

The Amendment after the Final rejection on 10/24/08 will be entered.; the Final rejection has been withdrawn.

**Examiner's Amendment and Reasons of Allowance**

**The Status of Claims**

Claims 1-6,8-11,16-17, and 20 are pending.

Claims 1-6,8-11,16-17, and 20 are allowable.

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with an attorney of record, Amid E. Schmid on 11/20/08 .

2. The application has been amended as follows:

In claim 1, lines 1-2, on page 2 (the amendment dated on 10/24/08), the phrase "-- or a pharmaceutically acceptable salt thereof, which is --" before the term "represented" is removed.

In claim 1, line 16, on page 4 (the amendment dated on 10/24/08), the phrase "-- , or a pharmaceutically acceptable salt thereof-- " is inserted after " (wherein R<sup>13</sup> and R<sup>14</sup> are the same as defined above)".

In claim 2, lines 1-2, on page 4 (the amendment dated on 10/24/08), the phrase “-- or a pharmaceutically acceptable salt thereof--” before the term “of” is removed.

In claim 2, line 3, on page 4 (the amendment dated on 10/24/08), the phrase “-- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “C1-3 lower alkyl group”.

In claim 3, lines 1-2, on page 4 (the amendment dated on 10/24/08), the phrase “-- or a pharmaceutically acceptable salt thereof--” before the term “of” is removed.

In claim 3, line 3, on page 4 (the amendment dated on 10/24/08), the phrase “-- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “C3-5 lower alkyl group”.

In claim 4, lines 1-2, on page 4 (the amendment dated on 10/24/08), the phrase “-- or a pharmaceutically acceptable salt thereof--” before the term “of” is removed.

In claim 4, line 3, on page 4 (the amendment dated on 10/24/08), the phrase “-- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “-(CH<sub>2</sub>)<sub>m</sub>-Y-(CH<sub>2</sub>)<sub>q</sub>-”.

In claim 5, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “-- or a pharmaceutically acceptable salt thereof--” before the term “of” is removed.

In claim 5, line 3, on page 5 (the amendment dated on 10/24/08), the phrase “-- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “-(CH<sub>2</sub>)<sub>m</sub>-Y-(CH<sub>2</sub>)<sub>q</sub>-”.

In claim 6, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase “-- or a pharmaceutically acceptable salt thereof--” before the term “of” is removed.

In claim 6, line 6, on page 5 (the amendment dated on 10/24/08), the phrase “-- , or a pharmaceutically acceptable salt thereof-- ” is inserted after “ lower cycloalkoxy group”.

In claim 8, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase "-- or a pharmaceutically acceptable salt thereof--" before the term "of" is removed.

In claim 8, line 3, on page 5 (the amendment dated on 10/24/08), the phrase "--, or a pharmaceutically acceptable salt thereof--" is inserted after " $-(CH_2)_2-Y-(CH_2)_2-$ ".

In claim 9, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase "-- or a pharmaceutically acceptable salt thereof--" before the term "of" is removed.

In claim 9, line 3, on page 5 (the amendment dated on 10/24/08), the phrase "--, or a pharmaceutically acceptable salt thereof--" is inserted after "methyl group".

In claim 10, lines 1-2, on page 5 (the amendment dated on 10/24/08), the phrase "-- or a pharmaceutically acceptable salt thereof--" before the term "of" is removed.

In claim 10, line 8, on page 5 (the amendment dated on 10/24/08), the phrase "--, or a pharmaceutically acceptable salt thereof--" is inserted after "methyl group".

In claim 11, lines 1-2, on page 6 (the amendment dated on 10/24/08), the phrase "-- or a pharmaceutically acceptable salt thereof--" before the term "of" is removed.

In claim 11, line 4, on page 6 (the amendment dated on 10/24/08), the phrase "--, or a pharmaceutically acceptable salt thereof--" is inserted after "C1-4 lower alkoxy group".

In claim 16, line 2, on page 6 (the amendment dated on 10/24/08), the phrase "-- a hydroxamic acid compound, or a pharmaceutically acceptable salt thereof--" after the term "administering" is replaced with the phrase "the hydroxamic acid compound or pharmaceutically acceptable salt thereof".

In claim 20, line 2, on page 6 (the amendment dated on 10/24/08), the phrase “ -- a pharmaceutically acceptable salt thereof --” after the terms “ the hydroxamic acid compound ” is replaced with the phrase “pharmaceutically acceptable salt thereof”.

3.. The following is an examiner's statement of reasons for allowance:

- The objection of Claims 1 and 6 has been withdrawn due to the modification of the claims.
- The rejection of Claims 15 and 18 under 35 U.S.C. 112, first paragraph or second paragraph has been withdrawn due to the cancellation of the claims.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.

Any inquiry concerning the communication after allowance such as sending all post-allowance correspondence should be directed to “ Box Issue Fee” or faxed directly to PUBS at 703-305-8755. This will expedite the process of these papers.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Taylor Victor Oh/  
Primary Examiner, Art Unit 1625  
11/20/08